The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma.
 
Alain Patrick Algazi
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; OncoSec
 
Adele H. Muthukumar
No Relationships to Disclose
 
Kelly O'Brien
No Relationships to Disclose
 
Alex Lencioni
No Relationships to Disclose
 
Katy K. Tsai
No Relationships to Disclose
 
Maha Kadafour
No Relationships to Disclose
 
Paul B. Chapman
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Momenta Pharmaceuticals; Provectus
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Momenta Pharmaceuticals; Provectus
Research Funding - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)